ABSTRACT
Objective To investigate the correlation between TRIM29 expression and non-small cell lung cancer (NSCLC) and its different histological types and clinicopathological features. Methods Using computer retrieves data databases such as PubMed, EMbase, China Knowledge Network and Wanfang Data, and collects relevant case-control studies at home and abroad. The time for searching the literature is as of August 1, 2018. Meta-analysis of the relationship between TRIM29 positive expression and clinicopathological features and tissue typing of non-small cell lung cancer was conducted by Review Manager 5.3 software. Results Five studies were included, including 1061 in the NSCLC group and 918 in the control group. Meta-analysis showed statistically significant differences between the expression of TRIM29 between NSCLC group and the control group [OR=18.32, 95％CI (4.62, 72.67), P<0.0001], squamous cell carcinoma and adenocarcinoma group [OR=37.05, 95％CI (2.45, 559.73), P=0.009], NSCLC lymph node metastasis group and NSCLC lymph node without metastasis group [OR=5.62, 95％CI (2.83, 11.17), P<0.00001], NSCLC (Ⅰ+Ⅱ) and (Ⅲ+Ⅳ) [OR=0.18, 95％CI (0.10, 0.32), P<0.00001] and NSCLC well differentiated group and the NSCLC middle and low differentiated group [OR=0.12, 95％CI (0.07, 0.21), P<0.00001], respectively. Conclusions The expression of TRIM29 is significantly correlated with NSCLC and its histological classification, lymph node metastasis, clinical stage and histological grade. This paper has certain help and reference value for the histological and clinical pathological features of NSCLC patients.
ABSTRACT
PURPOSE: TRIM29 overexpression has been reported in several human malignancies and showed correlation with cancer cell malignancy. The aim of the current study is to examine its clinical significance and biological roles in human bladder cancer tissues and cell lines. MATERIALS AND METHODS: A total of 102 cases of bladder cancer tissues were examined for TRIM29 expression by immunohistochemistry. siRNA and plasmid transfection were performed in 5637 and BIU-87 cell lines. Cell Counting Kit-8, flow cytometry, western blot, and real-time polymerase chain reaction were performed to examine its biological roles and mechanism in bladder cancer cells. RESULTS: We found that TRIM29 overexpression showed correlation with invading depth (p=0.0087). Knockdown of TRIM29 expression in bladder cancer cell line 5637 inhibited cell growth rate and cell cycle transition while its overexpression in BIU-87 cells accelerated cell proliferation and cell cycle progression. TRIM29 overexpression also inhibited cell apoptosis induced by cisplatin. In addition, we demonstrated that TRIM29 depletion decreased while its overexpression led to upregulated expression of cyclin D1, cyclin E, and Bcl-2. We also showed that TRIM29 knockdown inhibited protein kinase C (PKC) and nuclear factor κB (NF-κB) signaling while its overexpression stimulated the PKC and NF-κB pathways. BAY 11-7082 (NF-κB inhibitor) partly attenuated the effect of TRIM29 on expression of cyclin and Bcl-2. Treatment with PKC inhibitor staurosporine resulted in ameliorated TRIM29 induced activation of NF-κB. CONCLUSION: The current study demonstrated that TRIM29 upregulates cyclin and Bcl family proteins level to facilitate malignant cell growth and inhibit drug-induced apoptosis in bladder cancer, possibly through PKC–NF-κB signaling pathways.